Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 6, 2005, Pages 675-688

  Herman, Gary A ^a   Stevens, Cathy ^b   Van Dyck, Kristien ^b   Bergman, Arthur ^b   Yi, Bingming ^b   De Smet, Marina ^b   Snyder, Karen ^b   Hilliard, Deborah ^b   Tanen, Michael ^b   Tanaka, Wesley ^b   Wang, Amy Q ^b   Zeng, Wei ^b   Musson, Donald ^b   Winchell, Gregory ^b   Davies, Michael J ^b   Ramael, Steven ^b   Gottesdiener, Keith M ^b   Wagner, John A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 OXO 4 [3 (TRIFLUOROMETHYL) 5,6 DIHYDRO[1,2,4]TRIAZOLO[4,3 A]PYRAZIN 7(8H) YL] 1 (2,4,5 TRIFLUOROPHENYL)BUTAN 2 AMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG TOLERABILITY; EYE IRRITATION; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HEADACHE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD26; AREA UNDER CURVE; BLOOD GLUCOSE; C-PEPTIDE; COMMON COLD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EYE DISEASES; FASTING; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HEADACHE; HUMANS; INSULIN; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 28844482322     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.09.002     Document Type: Article

References (30)

1. S. Wild, G. Roglic, A. Green, R. Sicree, H. King Global prevalence of diabetes estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053
2. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes scientific review JAMA 287 2002 360 372
3. J.B. Saaddine, M.M. Engelgau, G.L. Beckles, E.W. Gregg, T.J. Thompson, K.M. Narayan A diabetes report card for the United States quality of care in the 1990s Ann Intern Med 136 2002 565 574
4. B. Ahren Gut peptides and type 2 diabetes mellitus treatment Curr Diab Rep 3 2003 365 372
5. D.J. Drucker Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin Investig Drugs 12 2003 87 100
6. L.A. Sorbera, L. Revel, J. Castaner P32/98 antidiabetic dipeptidyl-peptidase IV inhibitor Drugs Future 26 2001 859 864
7. E.B. Villhauer, G.M. Coppola, T.E. Hughes DPP-IV inhibition and therapeutic potential Ann Rep Med Chem 36 2001 191 200
8. T.J. Kieffer, J.F. Habener The glucagon-like peptides Endocr Rev 20 1999 876 913
9. R. Mentlein, B. Gallwitz, W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 214 1993 829 835
10. B. Balkan, L. Kwasnik, R. Miserendino, J.J. Holst, X. Li Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats Diabetologia 42 1999 1324 1331
11. B. Ahren, M. Landin-Olsson, P.A. Jansson, M. Svensson, D. Holmes, A. Schweizer Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89 2004 2078 2084
12. B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.A. Jansson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869 875
13. B. Ahren, R. Gomis, E. Standl, D. Mills, A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 2004 2874 2880
14. C.F. Deacon Therapeutic strategies based on glucagon-like peptide 1 Diabetes 53 2004 2181 2189
15. J.A. Pospisilik, J. Martin, T. Doty, J.A. Ehses, N. Pamir, F.C. Lynn Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741 750
16. M.K. Reimer, J.J. Holst, B. Ahren Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice Eur J Endocrinol 146 2002 717 727
17. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929 2940
18. J. Buse, R. Henry, J. Han, D.D. Kim, M. Fineman, A.D. Baron Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [abstract] Diabetes 52 Suppl 2 2004 A82
19. F. Calara, K. Taylor, J. Han, M. Aisporna, E. Zabala, E.M. Carr Effect of injection site on relative bioavailability of exenatide (synthetic exendin-4) [abstract] Diabetes 52 Suppl 2 2004 A120
20. T.H. Poon, P. Nelson, K. Love, L. Shen, T.A. Bicsak, K. Taylor Twenty-eight day dose-response study with exenatide (synthetic exendin-4) in subjects with type 2 diabetes treated with metformin or with diet and exercise [abstract] Diabetes 52 Suppl 2 2004 A142
21. D. Kim, L. Wang, M. Beconi, G. Eiermann, M. Fisher, H. He (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 48 2005 141 151
22. G.R. Lankas, B. Leiting, R. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 54 2005 2988 2994
23. B. Leiting, E. Nichols, T. Biftu, S. Edmondson, H. Ok, A.E. Weber Inhibition of dipeptidyl peptidase IV does not attenuate T-cell activation in vitro [abstract] Diabetes 52 Suppl 2 2004 A2
24. A.Q. Wang, W. Zeng, L. Chen, A.L. Fisher, D.G. Musson Automated online extraction and tandem mass spectrometry for the analysis of compound I in human plasma Proceedings of the Pharmaceutical and Biomedical Analysis Fifteenth Annual Symposium; 2004 May 2-6; Florence, Italy 2004 The Symposium Florence [abstract].
25. W. Zeng, A.L. Fisher, D.G. Musson, A.Q. Wang High-throughput liquid chromatography for drug analysis in biological fluids investigation of extraction column life J Chromatogr B Analyt Technol Biomed Life Sci 806 2004 177 183
26. H.O. Hartley The modified Gauss-Newton method for the fitting of non-linear regression functions by least squares Technometrics 3 1961 269 280
27. P. Wong, S. Mukhopadhyay, H. Quan, P. Larson American Statistics Association Confidence intervals for between-treatment mean difference when analysis is on the log percent scale Proceedings of the Biopharmaceutical Section 1999 American Statistics Association Baltimore 111 116 Aug 8-12.
28. C. Qualmann, M.A. Nauck, J.J. Holst, C. Orskov, W. Creutzfeldt Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects Acta Diabetol 32 1995 13 16
29. R. Ritzel, C. Orskov, J.J. Holst, M.A. Nauck Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships Diabetologia 38 1995 720 725
30. G.A. Herman, P.-L. Zhao, B. Dietrich, G. Golor, A. Schrodter, B. Keymeulen The DP-IV inhibitor MK-043 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics [abstract] Diabetes 52 Suppl 2 2004 A82